Eli Lilly and Co
NYSE:LLY

  • LAST PRICE
    886.7100
  • TODAY'S CHANGE (%)
    0.7700 (0.0869%)
  • Bid / Lots
    886.5800/ 2
  • Ask / Lots
    887.4900/ 2
  • Open / Previous Close
    888.8300 / 885.9400
  • Day Range
    884.3550
    890.7000
  • 52 Week Range
    516.5700
    972.5300
  • Volume
    389,301

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 1 hour ago by PR Newswire
      Companies Mentioned: LLY, PFE, ANVS

      NetworkNewsWire Editorial Coverage

      Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (FDA) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer's. However, there is no molecule or a combination of molecules that enhance cognitive functions. Thanks to innovative approaches by companies such asAnnovis Bio Inc. (NYSE: ANVS) (profile),there is reason to be optimistic about potential future breakthroughs in the AD space. Annovis has completed early research with compelling results utilizing its lead drug, buntanetap, in combination with popular drugs approved for other indications.Broadly speaking, there is ample reason to be bullish on new treatments for a variety of significant diseases, including AD and obesity, as companies such as Eli Lilly (NYSE: LLY), Pfizer Inc. (NYSE: PFE),Novo Nordisk (NYSE: NVO) and AbbVie Inc. (NASDAQ: ABBV) are making investments and progress on historically hard-to-treat diseases.

  • Yesterday

  • Sep 27, 2024

      Show headlines and story abstract

    • 9:48PM ET on Friday Sep 27, 2024 by Dow Jones
      Companies Mentioned: LLY, RVMD, IPSC, GPCR

      In the event of a Republican victory, the tone could change in two ways: The mergers-and-acquisitions landscape could be more fluid and affable compared with the past four years. That won't benefit healthcare more than other sectors, but healthcare is a leader in consolidation. The biotech industry would be an obvious beneficiary. And, given that two pharma companies are closing in on a trillion dollars of enterprise value and UnitedHealth is six times as big as most peers, we could set the stage for a merger of equals, which hasn't been discussed in this industry for years.

    • 9:30PM ET on Friday Sep 27, 2024 by Dow Jones
      Companies Mentioned: DXCM, LLY, NVO, AAPL, ABT

      Two weeks of wearing DexCom's patch-size Stelo glucose-monitoring device was a revelation. Who knew that I'd have to give up grapes? By Bill Alpert

      I survived 68 years without knowing my blood sugar levels. Ignorance is sweet.

    • 9:30PM ET on Friday Sep 27, 2024 by Dow Jones
      Companies Mentioned: LLY, RVMD, IPSC, GPCR

      In the event of a Republican victory, the tone could change in two ways: The mergers-and-acquisitions landscape could be more fluid and affable compared with the past four years. That won't benefit healthcare more than other sectors, but healthcare is a leader in consolidation. The biotech industry would be an obvious beneficiary. And, given that two pharma companies are closing in on a trillion dollars of enterprise value and UnitedHealth is six times as big as most peers, we could set the stage for a merger of equals, which hasn't been discussed in this industry for years.

Peers Headlines